RAD51 recombinase polymerizes at the site of double-strand breaks (DSBs) where it performs DSB repair. The loss of RAD51 causes extensive chromosomal breaks, leading to apoptosis. The polymerization of RAD51 is regulated by a number of RAD51 mediators, such as BRCA1, BRCA2, RAD52, SFR1, SWS1, and the five RAD51 paralogs, including XRCC3. We here show that brca2-null mutant cells were able to proliferate, indicating that RAD51 can perform DSB repair in the absence of BRCA2. We disrupted the BRCA1, RAD52, SFR1, SWS1, and XRCC3 genes in the brca2-null cells. All the resulting double-mutant cells displayed a phenotype that was very similar to that of the brca2-null cells. We suggest that BRCA2 might thus serve as a platform to recruit various RAD51 mediators at the appropriate position at the DNA–damage site.
Mutations in BRCA1 and BRCA2 predispose hereditary breast and ovarian cancer. Such mutations sensitize to chemotherapeutic agents, including camptothecin, cisplatin, and poly(ADP-ribose) polymerase (PARP) inhibitor, since RAD51 mediators including both BRCA proteins promote repair of DNA lesions induced by these drugs. Little is known of the functional relationships among RAD51, BRCA2, and other RAD51 mediators, because no brca2-null cells were available. Furthermore, the phenotype of sws1 mutants has not been documented. We here disrupted every known RAD51 mediator and analyzed the phenotype of the resulting mutants in both BRCA2-deficient and -proficient backgrounds. The understanding of the function of individual RAD51 mediators and their functional interactions will contribute to the accurate prediction of anti-cancer therapy efficacy.
Citation: Qing Y, Yamazoe M, Hirota K, Dejsuphong D, Sakai W, Yamamoto KN, et al. (2011) The Epistatic Relationship between BRCA2 and the Other RAD51 Mediators in Homologous Recombination. PLoS Genet 7(7): e1002148. https://doi.org/10.1371/journal.pgen.1002148
Editor: Michael Lichten, National Cancer Institute, United States of America
Received: December 3, 2010; Accepted: May 2, 2011; Published: July 14, 2011
Copyright: © 2011 Qing et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by a Grant-in-Aid for Scientific Research on Priority Areas and a Grant-in-Aid from the Special Coordination Funds for Promoting Science and Technology from the Ministry of Education, Culture, Sports, and Science of Japan and by grants from The Uehara Memorial Foundation and The Naito Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Homologous recombination (HR) maintains genome integrity by accurately repairing double-strand breaks (DSBs) that arise during the mitotic cell cycle or are induced by radiotherapy , . HR also plays an important role in releasing the replication forks that stall at damaged template DNA strands , . Thus, effective HR makes tumor cells tolerant to the chemotherapeutic agents that damage DNA and stall replicative DNA polymerases. Such chemotherapeutic agents include cis-diaminedichloroplatinum(II) (cisplatin), camptothecin, and poly(ADP-ribose) polymerase (PARP) inhibitors, including olaparib (AstraZeneca). Cisplatin is a crosslinking agent that generates intra- and inter-strand crosslinks and thereby stalls replicative DNA polymerases. Camptothecin inhibits the ligation of single-strand breaks (SSBs) that are formed during the normal functioning of topoisomerase 1. Resulting unrepaired SSBs are converted to DSBs upon replication. Similarly, PARP inhibitors interfere with SSB repair . Since HR plays a major role in repairing DNA lesions generated by camptothecin, cisplatin, and PARP inhibitors , measuring HR efficiency in individual malignant tumors may help predict the efficacy of these chemotherapeutic treatment for each tumor –.
HR-dependent DSB repair is accomplished by the following step-wise reactions . DSBs are processed by the Mre11/Rad50/Nbs1 complex and the CtIP, Exo1 and DNA2 nucleases to develop 3′ single-strand DNA (ssDNA) tails –. RAD51, an essential recombinase, polymerizes on these ssDNAs, leading to the formation of nucleoprotein filaments. These filaments undergo homology search and subsequent invasion into homologous duplex DNA to form a D-loop structure, where they serve as a primer for DNA synthesis , . After the extended end is displaced from the D-loop, it anneals to its partner-end to complete DSB repair. We know that RAD51 plays a key role in HR in vertebrate cells, as inactivation of RAD51 results in the accumulation of chromosomal breaks in mitotic cells and inhibits the completion of even a single cell cycle , . The polymerization of RAD51 at damage sites is strictly regulated by a number of accessory factors (hereafter called RAD51 mediators), including the five RAD51 paralogs, SWS1, RAD52, SFR1, BRCA1, BRCA2, and PALB2 , –. The functional relationships of these RAD51 mediators are poorly understood, because cells deficient in multiple RAD51 mediators have not been established.
BRCA2 was originally identified as a tumor suppressor, as germline mutation of the BRCA2 gene results in a high risk of developing breast, ovarian, pancreatic, prostatic, and male breast cancer , , , . BRCA2 is recruited to processed DSBs, and facilitates the assembly of RAD51 at the single-strand tail. The middle of the BRCA2 protein has eight BRC repeats, comprising 26 amino acids. Biochemical studies have revealed that individual BRC repeats prompt the loading of RAD51 on ssDNA , . Since no brca2-null cells have been established, the function of BRCA2 has been postulated from the phenotypic analysis of mice carrying an allele, extending from the N-terminus to the BRC3 motif (hereafter brca2tr) that encodes a truncated form of BRCA2. Cells derived from brca2tr mice and brca2tr DT40 cells are able to proliferate and exhibit increased sensitivity to ionizing radiation, camptothecin, and cisplatin , . It remains unclear whether brca2 null cells display the same phenotype as do rad51 cells, or a milder phenotype.
The roles of the RAD51 mediators have been characterized by phenotypic analysis of their mutants. Mammalian brca1-deficient cells show normal focus formation of the RPA ssDNA binding protein but diminished RAD51 focus formation at DSBs, indicating that BRCA1 facilitates the polymerization of RAD51 after the resection of DSBs , . DT40 cells deficient in any one of the five RAD51 paralogs show a very similar phenotype, including compromised RAD51 focus formation and the same degree of DNA damage sensitivity , , suggesting that these five proteins form a functional unit in the promotion of RAD51 polymerization in which each RAD51 paralog is essential for its function. No biochemical studies have yet defined the molecular mechanisms underlying the promotion of RAD51 assembly by BRCA1, the RAD51 paralogs, or SWS1. SWS1 is another RAD51 mediator , and sws1-deficient vertebrate cells have not yet been reported. SFR1 was originally identified in fission yeast , and its role in in vitro HR reactions ,  as well as the phenotypic analysis of sfr1-deficient mice have been recently reported . The biochemical character of full-length human BRCA2 has been recently documented, whereas no biochemical studies have defined its functional interaction with other RAD51 mediators or the molecular mechanisms underlying the promotion of RAD51 assembly by BRCA1, the RAD51 paralogs, or SWS1 –.
In this paper, we addressed the function of Rad51 mediators and their relationship in DNA-damage responses. We generated the single Rad51 mediator mutant cells, including brca2 null, sfr1 and sws1 deficient cells from DT40 chicken cell line . We also disrupted the BRCA1, one of the RAD51 paralogs (XRCC3), RAD52, RAD54, SWS1, and SFR1 in brca2 null deficient DT40 cells. The phenotypes of these cells were analyzed to reveal hierarchical relationship of RAD51, BRCA2, and the other RAD51 mediators, where RAD51 is able to operate HR without BRCA2 while BRCA2 is required for the functioning of the other RAD51 mediators. Hence, BRCA2 might serve as a platform to recruit various RAD51 mediators at the appropriate position of DNA-damage sites. Our study sheds light on the functional relationship of RAD51 and every known RAD51 mediators for the first time, and thereby significantly contributes to the development of effective anti-cancer therapies.
Loss of SFR1 or SWS1 has a limited impact on DNA–damage responses
To analyze SFR1 and SWS1, we disrupted the SFR1 and SWS1 genes in DT40 cells (Figure 1A–1D). Table 1 summarizes the selection marker genes we used to disrupt genes in this study. The resulting sfr1 and sws1 mutant clones proliferated with nearly normal kinetics (Figure 2) and exhibited an increase in cellular sensitivity to cisplatin. The sfr1 mutant was sensitive also to camptothecin and olaparib (Figure 3). Both mutants showed a slight but significant decrease in ionizing-radiation-induced RAD51 focus formation (Figure 4). We conclude that SFR1 and SWS1 indeed work as RAD51 mediators, though their contribution to HR-dependent repair is less significant than that of BRCA1, BRCA2, and the RAD51 paralogs.
(A) Schematic representation of the endogenous SFR1 locus and gene-disruption constructs carrying the puro or bsr selection marker gene. The solid boxes represent exons, and numbers right above boxes represent exon numbers. Relevant BamHI and EcoRI sites are indicated. (B) Southern-blot analysis of genomic DNA digested by both BamHI and EcoRI was performed using the probe DNA shown in (A). Positions of hybridizing fragments of wild-type (WT) and targeted loci are indicated. (C) Schematic representation of the endogenous SWS1 locus and gene-disruption constructs carrying the puro or his selection marker gene. Relevant EcoRV and NotI sites are indicated. (D) Southern-blot analysis of genomic DNA digested by EcoRV and NotI was performed with the probe DNA shown in (C). (E) Experimental methods to generate BRCA2−/− and RAD51mediator−/−/BRCA2−/− cells. We generated BRCA2−/− cells from conditional mutant BRCA2−/con1 cells. In the minus allele of the BRCA2−/con1 cells, the whole coding sequence is deleted (hereafter called the coding sequence deletion allele). The structures of the conditional-null allele-1 (con1) is shown in (F). Treatment of BRCA2−/con1 cells with 4-OH tamoxifen (TAM) led to the generation of BRCA2−/− cells. To generate RAD51mediator−/−/BRCA2−/− cells, we disrupted one of the RAD51mediator genes in BRCA2−/con1 cells. Exposure of the resulting RAD51mediator−/−/BRCA2−/con1 cells to TAM led to the generation of RAD51mediator−/−/BRCA2−/− cells. (F) Schematic representation of BRCA2 conditional-null allele and the brca2-null allele wherein the whole coding sequences are deleted. The conditional-null allele-1 (con1) shown on top was described previously ; the structure of the coding sequence deletion allele is shown in the second row. Treatment of the BRCA2−/con1 cells with TAM causes deletion of the promoter and initiation codon. The relevant EcoRI sites in the conditional-null allele-1, the relevant XbaI sites in the coding sequence deletion allele, and the position of the probes used in the Southern-blot analysis (G) are indicated. The solid boxes and arrowheads represent the exons and loxP signals, respectively. (G) Southern-blot analysis of the conditional allele (left) and the other coding sequence deletion (−) allele (right) in BRCA2−/con1 cells with (+) or without (−) TAM treatment. Southern-blot analysis of EcoRI or XbaI-digested genomic DNA was performed with the probe DNA shown in (F). (H) Western-blot analysis to verify the loss of BRCA2 protein in BRCA2−/− cells derived from BRCA2−/con1 cells.
(A) Growth curve for cells of the indicated genotype. (B) The relative rate of cell growth per 8 hours (a single cell cycle for wild-type cells) plotted for cells carrying the indicated genotypes. Each value represents the averaged results from three separate experiments. Error bars represent standard deviation. (C) Cell-cycle distribution of brca2-null cells that were pulse-labeled with BrdU for 10 minutes and subsequently stained with FITC-conjugated anti-BrdU antibody (Y-axis, log scale) and propidium iodide (PI) (X-axis, linear scale). The upper gate indicates cells incorporating BrdU (S phase), the lower middle gate indicates G1 cells, and the lower-right gate indicates G2/M cells. The sub G1 fraction (lower-left gate) indicates dead cells. The number in each gate indicates the percentage of gated events.
(A) Cells of the indicated genotype were exposed to camptothecin for 72 hours, a period during which wild-type cells are able to divide nine times in the absence of exogenous DNA damage. The X-axis represents the concentration of camptothecin and the Y-axis represents the relative number of surviving cells at 72 hours. The vertical dotted lines show LC50 values (the concentration of camptothecin that reduces cellular survival to 50% relative to cellular survival without camptothecin treatment). Relative LC50 values of camptothecin (B), cisplatin (C), and Poly(ADP-ribose) polymerase inhibitor olaparib (D and E) are shown. Values shown are mean ± SD.
(A) Immuno-staining of irradiated wild-type and mutant DT40 clones using anti-RAD51 antibody. Cells were fixed 3 hours after irradiation with 4Gy γ-rays. Bar, 10 µm. (B) Quantification of RAD51 foci in individual cells of the indicated genotype. Data shown are the means of three experiments. Error bars indicate standard deviation. Statistical analysis was performed using the t test. * P<0.01 compared to wild-type.
The brca2-null mutant is capable of proliferating
To create brca2-null cells, we generated compound heterozygous mutant cells (hereafter called BRCA2−/con1 cells) (Figure 1E). The whole coding sequence was deleted in the minus (−) allele of the -/conditional-null allele-1 (-/con1) genotype of the BRCA2−/con1 cells (Coding sequence deletion allele in Figure 1F). We conditionally deleted the con1 allele of the BRCA2−/con1 cells by adding tamoxifen, which activated the chimeric Cre recombinase  and thereby eliminated the promoter and coding sequences, including exons 1 and 2 of the con1 BRCA2 allelic gene (BRCA2 conditional-null allele-1 in Figure 1F). At day two of continuous tamoxifen treatment, the vast majority of cells lost the intact BRCA2 gene in the conditional allele, and a substantial fraction of cells began to die. To our surprise, we were able to reproducibly establish clonally expanding cells wherein the conditional BRCA2 allele was deleted (BRCA2−/− cells, hereafter called brca2-null cells) from 10 to 20% of the tamoxifen-treated populations. We verified deletion of the BRCA2 allele in the established clones by Southern-blot (Figure 1G) and western-blot (Figure 1H) analysis. The ability of the brca2-deleted cells to proliferate is in marked contrast to the immediate cell death observed in rad51-deleted cells . The plating efficiency of the brca2-null clones was around 20%, which is significantly lower than that of the wild-type (100%) and brca2tr (60%) cells .
One obvious concern with this experiment was that expression of the N-terminal-truncated BRCA2 protein in the Cre-mediated deletion lines could allow for residual function. We therefore created a second version of the conditionally inactivated BRCA2 allele, wherein sequences spanning from the promoter to intron 12 could be eliminated by induction of Cre (BRCA2 conditional-null allele-2 in Figure S1). We exposed the resulting compound heterozygous mutant cells to tamoxifen and confirmed reproducible establishment of BRCA2-deleted clones (Text S1). This second brca2 conditional-null allele supported proliferation with generation times very similar to those of the first version of the brca2-null cells (data not shown). The more extensively deleted brca2 clones showed a phenotype indistinguishable from that of the smaller deletion clones, indicating that both deletions confer the null phenotype.
BRCA2 contributes to genome maintenance to a lesser extent than does RAD51
We assessed the proliferative properties of brca2-null clones by monitoring their growth curve (Figure 2A and 2B) and cell cycle (Figure 2C). Wild-type cells doubled every 8 hours and increased in cell number by 64 times over 48 hours. The brca2-null cells increased by 17 times over 48 hours (Figure 2A), calculated as a 1.6-fold increase over 8 hours (1.66 = 17) (Figure 2B). The number of brca1, brca2tr, and xrcc3 clones  increased 1.6, 1.9, and 1.8 fold, respectively, over eight hours. The reduced growth kinetics of the brca2-null cells is partly due to apoptosis in a substantial fraction of the cell population, as evidenced by the accumulation of cells in a sub-G1 fraction (Figure 2C).
To understand the cause of this cell death, we measured the number of chromosome breaks in mitotic cells. Forty-six chromosomal aberrations were detectable in 100 mitotic brca2-null cells, larger than the number of aberrations observed in any other RAD51-mediator mutants (Table 2). We therefore conclude that spontaneously arising DSBs resulted in cell death in a fraction of brca2-null cells, thus accounting for the reduced growth kinetics (Figure 2A and 2B). The viability of the brca2-null cells reveals that BRCA2 plays a less important role than does RAD51 in the maintenance of genome integrity . The high number of spontaneously arising chromosomal breaks in the brca2-null cells (Table 2) shows that BRCA2 plays a more fundamental role in genome maintenance than do any of the other RAD51 mediators.
brca2-null cells displayed a stronger phenotype than the brca1, brca2tr, and rad51 paralog mutant clones
We analyzed cellular tolerance to camptothecin, cisplatin, and olaparib by measuring cellular survival at 72 hours (7–9 cell cycles) after continuous exposure to these agents in a liquid medium. We did not use the conventional colony-formation assay for this analysis, because the plating efficiency of the brca2-null cells was only 20%, 5-fold lower than that of wild-type cells. Figure 3A presents an example of cellular sensitivity to camptothecin, a DNA-damaging agent. Subsequent figures illustrate the sensitivity of each mutant, assessed by LC50 values, i.e., the dose that reduces cell survival to 50% relative to the LC50 value of wild-type cells, which is defined as 100% (Figure 3B–3E).
In the cellular-survival analysis, the brca2-null cells showed an increased sensitivity to camptothecin (Figure 3B), cisplatin (Figure 3C), and olaparib (Figure 3D and 3E). Moreover, sensitivity to cisplatin and olaparib was higher with the brca2-null cells than for any of the other HR mutant cells, including the brca1, rad52, rad54, and xrcc3 clones (Figure 3). We therefore conclude that BRCA2 plays a more important role in HR-dependent repair than do the other RAD51 mediators, including BRCA1, RAD52, RAD54, the RAD51 paralogs, SFR1, and SWS1.
The less prominent phenotype of the brca2tr cells compared to the brca2-null cells indicates that the BRCA2 BRC3-truncated protein retains significant residual HR function. Although brca1 cells were less sensitive to cisplatin and olaparib than were brca2-null cells, the brca1-null cells exhibited a slightly higher sensitivity to camptothecin than did the brca2-null cells (Figure 3A). The greater contribution of BRCA1 to cellular tolerance to camptothecin might be attributable to the role played by BRCA1 in DNA-damage responses other than HR, such as collaborative action with CtIP to eliminate covalently bound oligo-peptides from DSBs .
We next measured the frequency of HR-dependent repair of I-Sce1-mediated DSBs in a recombination substrate, SCneo, inserted into the OVALBUMIN locus ,  (Table 3). The frequency of HR-dependent DSB repair was calculated as the number of neomycin-resistant (neo+) colonies relative to the number of plated cells. The frequency of HR in the brca2-null, brca2tr, and brca1 cells was decreased by 1.5×104-, 1.5×102-, and 4.5×103-fold, respectively, compared with wild-type cells. We conclude that the brca2-null cells retain residual HR activity, which may account for their viability even in the complete absence of BRCA2.
Since BRCA2 promotes the loading of RAD51 at damage sites, we measured RAD51 focus formation at 3 hours after ionizing radiation. The number of RAD51 foci was reduced but not eliminated in the brca1 and brca2tr clones, compared with wild-type cells (Figure 4). These findings are consistent with previous observations , . By contrast, we hardly detected any RAD51 focus formation in the brca2-null cells. In conclusion, the BRCA2 protein plays a key role in the efficient recruitment of RAD51 to DNA-damage sites, but is not essential for every HR reaction.
BRCA2 is required for the effective participation of BRCA1, RAD52, SFR1, SWS1, and XRCC3 in HR
The idea that RAD51 carries out HR even without BRCA2 led us to investigate whether or not other RAD51 mediators substitute for BRCA2 in the promotion of RAD51-dependent HR. To this end, we deleted the BRCA1, RAD52, SFR1, SWS1, and XRCC3 genes in the conditional brca2-null background, then inactivated the BRCA2 gene by treating the cells with tamoxifen (Figure 1E). We also disrupted the RAD54 gene in the conditional brca2-null background (Table 1). The RAD54 protein promotes HR after the assembly of RAD51 at DNA-damage sites . To our surprise, we were able to reproducibly establish all resulting double mutants, although a substantial fraction (∼30%) of the brca2-null cells died each cell cycle.
The growth kinetics for the brca1/brca2-null, rad52/brca2-null, sfr1/brca2, sws1/brca2-null, and xrcc3/brca2-null double-mutant clones was similar to those of the brca2-null single mutant (Figure 2). Taking the very severe phenotype of brca1 cells into account, the viability of the brca1/brca2-null cells was surprising. The cloning efficiency of the brca1/brca2-null cells was slightly higher than that of the brca2-null single-mutant cells (30% compared to 20%). Accordingly, the number of spontaneous chromosomal aberrations in the brca1/brca2-null cells was consistently slightly lower than that in the brca2-null cells (Table 2). In summary, although the loss of either BRCA1 or BRCA2 greatly increased the number of spontaneous chromosomal breaks, inactivation of BRCA1 in the brca2-null cells resulted in a slight reduction in the severity of the brca2 phenotype.
An early study shows rad52/xrcc3 double-mutant cells are synthetic lethal and exhibit numerous chromosomal breaks , whereas we here found that the brca2/rad52 and brca2/xrcc3 double-mutant cells were viable. Thus, the synthetic lethality might be attributable to BRCA2 mediated formation of toxic HR intermediates, because the brca2/xrcc3 cells exhibit spontaneously arising isochromatid breaks, where two sisters are broken at the same site due to defective completion of HR . To test this hypothesis, we conditionally inactivated the BRCA2 gene in the rad52/xrcc3 cells (Text S1). We found that the inactivation of the BRCA2 gene indeed rescued the rad52/xrcc3 cells (Figure S2). This observation indicates that the synthetic lethality of the rad52/xrcc3 cells does not argue against the idea that the functioning of RAD52 and XRCC3 depends on BRCA2. Likewise, the formation of toxic HR intermediates might explain the apparent discrepancy between the viability of rad52/brca2-null DT40 cells and the mortality caused by shRNA mediated depletion of RAD52 in brca2 deficient mammalian cells , as the latter cells express a residual amount of RAD52 and truncated BRCA2 proteins perhaps leading to the formation of toxic HR intermediates.
We next measured the sensitivity of the brca1/brca2-null, rad52/brca2-null, rad54/brca2-null, sfr1/brca2-null, sws1/brca2-null, and xrcc3/brca2-null double-mutant clones to camptothecin, cisplatin, and olaparib (Figure 3 and Figure 5). Remarkably, inactivation of any gene did not increase cellular sensitivity to the three damaging agents by more than two-fold. This observation indicates that the contribution made by BRCA1, the RAD51 paralogs, RAD52, RAD54, SFR1, and SWS1 to HR depends mostly on BRCA2. Interestingly, the loss of BRCA1, SFR1, and SWS1 somewhat increased the cellular tolerance of the brca2-null cells to cisplatin. Similarly, the loss of SWS1 increased the cellular tolerance of the brca2-null cells to camptothecin and olaparib. This increased tolerance was not accompanied by the upregulation of RAD51 focus formation (data not shown). We therefore suggest that, in the absence of BRCA2, SWS1 has a moderately antagonistic effect on HR-dependent repair. By contrast, the loss of RAD52 and XRCC3 significantly increased the cellular sensitivity of the brca2-null cells to olaparib. In summary, BRCA2 is required for all the analyzed RAD51 mediators to function, and the functional relationships between BRCA2 and the other RAD51 mediators in HR-mediated repair differ slightly depending on the type of DNA damage.
In this study, we established brca2-null cells as well as cells deficient in each of the RAD51 mediators. We show that BRCA2 plays a more important role in the promotion of both RAD51 polymerization at DNA-damage sites and HR-dependent repair than does any other RAD51 mediator, including BRCA1, the RAD51 paralogs, RAD52, SFR1, and SWS1. The ability of brac2-null cells to proliferate is in marked contrast with the immediate cell death that occurs upon depletion of RAD51 . Therefore, RAD51 is able to perform HR even in the absence of BRCA2. To explore the question of which RAD51 mediators might substitute for BRCA2 in the promotion of RAD51-dependent HR repair, we inactivated the RAD51 mediators in brca2-null cells. Loss of any one of the other RAD51 mediators did not further reduce the viability of brca2-null cells. In a related study, we also found that the brca2-null mutant and the palb2/brca2-null double mutant showed the same phenotype with respect to both spontaneous chromosomal aberrations and increased sensitivity to DNA-damaging agents (manuscript in preparation). Thus we conclude that BRCA1, PALB2, the RAD51 paralogs, RAD52, SFR1, and SWS1 all require BRCA2 to contribute to HR.
BRCA2 plays a major role in the recruitment of RAD51 to DNA–damage sites, but is not essential for every HR reaction
Data on Ustilago maydis  and Arabidopsis thaliana  suggest that BRCA2 might be essential for RAD51 to function in any HR reaction. However, we here report that RAD51 can form HR products even in brca2-null cells, indicating that RAD51 plays a more important role than BRCA2 in HR. This hierarchy between RAD51 and BRCA2 is supported by previous reports of experiments with mice, as rad51 null embryos died earlier (∼E6.5) than did BRCA2 null (∼E8.5) embryos , . The viability of brca2-null DT40 cells is consistent with the clonal expansion of BRCA2-deficient cells derived from mammary epithelial lineage-specific or T cell lineage-specific BRCA2-null-deficient mice , . Adding to these findings, we here show solid evidence that vertebrate RAD51 is capable of functioning in the absence of BRCA2.
Collaboration between BRCA1 and BRCA2 is required for efficient HR
The phenotypic analysis of brca1, brca2-null, and brca1/brca2-null clones, combining with the previous study of rad51-null cells, reveals the functional relationship described as follows. The capability of HR was dramatically diminished when either BRCA1 or BRCA2 was absent, indicating that the collaboration of BRCA2 and BRCA1 is required for efficient HR events. brca2-null cells exhibited more prominent defects in HR than did brca1-null cells, indicating that BRCA2 can function in HR independently of BRCA1. Moreover, BRCA2′s contribution to the repair of cisplatin-induced interstrand crosslinks is more significant than BRCA1, which is likely attributable to the fact that BRCA2, but not BRCA1, functions in the Fanconi anemia repair pathway . BRCA1 has additional functions other than in HR, such as mediating the damage checkpoint and processing DSBs , . The fact that rad51-null cells have a considerably stronger phenotype than brca2-null cells indicates that RAD51 could still perform HR-dependent repair in brca2-null cells.
The phenotypic similarities between the brca2-null and the brca1/brca2-null clones indicate that BRCA1 contributes to HR by collaborating with BRCA2. Presumably, the two BRCA proteins form a functional unit and collaborate intimately to load RAD51 at damage sites. This idea is supported by the fact that BRCA1 physically associates with BRCA2 through the PALB2 protein . However, this idea is challenged by recent studies that suggest that BRCA1 plays a role in the resection of DSBs , . One possible scenario is that the complex formation of BRCA1 and BRCA2 may allow for close collaboration between the BRCA1-dependent resection of DSBs and the subsequent loading of RAD51 on the resulting 3′ overhang. Such an interaction interface might be shared by the E. coli RecBCD complex, which serves as the DSB resection complex and also interacts directly with RecA following chi site recognition . In summary, the phenotypic analysis of brca1, brca2-null, and beca1/brca2-null DT40 clones demonstrates that BRCA1 controls RAD51 in HR, mainly through collaboration with BRCA2.
BRCA2 is required for BRCA1, PALB-2, the RAD51 paralogs, SFR1, and SWS1 to promote HR
Our study reveals that rad52/brca2-null, sfr1/brca2-null, sws1/brca2-null, and xrcc3/brca2-null clones exhibit a phenotype very similar to that of brca2-null cells (Figure 5). In a separate study, we conformed phenotypic similarity between brca2-null and palb2/brca2-null clones (data not shown). We therefore suggest that, like BRCA1, PALB2, the RAD51 paralogs, RAD52, SFR1, and SWS1 are also able to participate in HR, mostly depending on BRCA2. One possible scenario is that BRCA2 is recruited to DNA-damage sites through PALB2 or by directly interacting with the junction between the duplex DNA and the single-strand sequences . BRCA2 might thus serve as a platform to recruit various RAD51 mediators to the appropriate positions of DNA-damage sites (Figure 6).
In the absence of BRCA2, RAD51 polymer assembles at DNA damage sites (top), while BRCA2 significantly promotes the polymerization of RAD51 (bottom). This promotion is attributable to the requirement of BRCA2 for the appropriate localization of other RAD51 mediators at DNA damage sites. Accordingly, the loss of BRCA2 may result in the abnormal functioning of some RAD51 mediators, for example, SWS1. This scenario explains why the loss of SWS1 increased cellular tolerance to camptothecin, cisplatin, and olaparib only when BRCA2 was absent (Figure 3).
Applications for clinical research
DT40 is a unique cell line that offers a panel of DNA-repair-deficient isogenic mutants derived from a stable parental line. DT40 cells have several characteristics that affect cellular responses to anti-cancer agents. First, DT40 appears, for unknown reasons, to possess a significantly higher HR efficiency than any mammalian cell line . The efficient HR in DT40 cells is prominent particularly in HR between diverged homologous sequences such as Immunoglobulin V gene diversification  and gene targeting, where the selection marker genes of gene-disruption constructs may interfere with HR as heterologous sequences. Second, like many cancer cells, DT40 lacks the functional p53, and as a result has no G1/S damage checkpoint . In addition, 70% of the DT40 cell cycle takes place in the S phase. Thus, DNA damage at any phase of the cell cycle may have a direct impact on DNA replication. These characteristics, specific to DT40, suggest that a defect in DNA repair associated with DNA replication, including HR-mediated DNA repair, may display a more prominent phenotype in DT40 cells than in other cell lines that have a longer G1 phase and/or a normal G1/S checkpoint. Bearing this in mind, DT40 is revealed as a unique and valuable tool and has been used extensively to explore the role of individual HR factors responsible for cancer therapy.
Materials and Methods
Cell culture and DNA transfection
Cells were aquired and cultured as described previously , . All mutants were isolated from single colonies. DNA transfection and selection were performed as described previously , . Details of the cell lines used in this study are shown in Table 1.
Generation of SFR1−/− DT40 cells
To disrupt the SFR1 gene, we generated SFR1-puro and SFR1-bsr disruption constructs by combining two genomic PCR products with the puro- or bsr-selection-marker cassette. Genomic DNA sequences were amplified using the 5′-CCCGGTACTGAGGGGTGCGATTGCTTGCAGG-3′ and 5′-CCCTTAGAGTTGCACTCATTGGCTAAAG-3′ primers for the upstream arm, and the 5′-GGCTCAAACTGGTCAAGATGTACCGATCTAAGG-3′ and 5′-CCACCAGCATCCACTAAAGGGCAAGGAACG-3′ primers for the downstream arm. Amplified PCR products were cloned into pCR2.1-TOPO vector (Invitrogen). The 1.7 kb fragment of the upstream arm was cloned into the KpnI site of pCR2.1 containing the 3.0 kb downstream arm. Marker-gene cassettes were inserted at the BamHI site of the resulting plasmid.
To generate SFR1−/− cells, SFR1-puro and SFR1-bsr disruption constructs lineralized with NotI were transfected sequentially by electroporation (Bio-Rad). The genomic DNA of the transfectants was digested with both BamHI and EcoRI, and gene-targeting events were confirmed by Southern blot analysis. The probe was prepared from a PCR-amplification of DT40 genomic DNA using primers 5′-GAACAGCACCACGCAATTCA-3′ and 5′-CCTTAGAGTTGCACTCATTGG-3′.
Cloning of SFR1 cDNA
Chicken SFR1 cDNA was isolated by PCR amplification of the primary cDNAs using the 5′-GTTGAGATGGAGGAAGCAGCGTGTGGTAAA-3′ and 5′-CACCACTCAATTCCACTTCAAAGAG-3′ primers. The gene bank accession number of the chicken SFR1 gene is XM-001234167.
Generation of SWS1−/− DT40 cells
To disrupt the SWS1 gene, we generated SWS1 gene-disruption constructs containing the 2.6 kb upstream and the 3.0 kb downstream genomic fragments. The 2.6 kb fragment was PCR-amplified using the 5′-ggggacaactttgtatagaaaagttgTTCTTACGTCACTCCAGAAGAACA-3′ and 5′-ggggactgcttttttgtacaaacttgCCAAGTCTGTGAATCGCAGAAGCA-3′ primers. The 3.0 kb fragment was PCR-amplified using the 5′-ggggacagctttcttgtacaaagtggAATTCCAAGCAGTTCCACATCTCT-3′ and 5′-ggggacaactttgtataataaagttgGTATGGCTCCTGTCAGGTTAGAGT-3′ primers. Note that the underlined sequences denote the recognition sequences in the Gateway system (Invitrogen). Using the MultiSite Gateway system with pENTR-lox-his, pENTR-lox-puro and pDEST-DTA-MLS , a floxed his or puro gene was inserted between the upstream and downstream arms on a plasmid carrying a diphtheria toxin A (DT-A) gene, thus yielding the two targeting vectors, SWS1-his/loxP and SWS1-puro/loxP.
To generate SWS1−/− cells, SWS1-his/loxP and SWS1-puro/loxP gene-disruption constructs linearized with AscI were transfected sequentially into DT40 cells (Bio-Rad). The genomic DNA of the transfectants was digested with both EcoRV and NotI, and gene-targeting events were confirmed by Southern-blot analysis. The probe was prepared by PCR-amplification of chicken genomic DNA using the 5′-GCTCGCAGGAACACAACTCCTT-3′ and 5′-GTACAGGAGTGTTTCTCTGCGG-3′ primers.
Cloning of SWS1 cDNA
The gene bank accession numbers for the human and chicken Sws1 genes are XP-058899 and XP-415841, respectively. RT-PCR of DT40 transcripts was done using the 5′-CGCGTCGACATGGATAGCACCTTACCAGCT-3′ and 5′-CGCGGATCCTCATCCTTCATCCTCTTCCTC-3′ primers.
Generation of BRCA2−/− DT40 cells
The brca2-null mutant cells were generated as follows (Figure 1). We inserted conditional brca2 heterozygous cells (BRCA2+/con1) harboring two loxP signals into the other allele upstream of the promoter and downstream of exon 2. Construction of the BRCA2 conditional-null targeting vector was carried out as described previously . To delete the intact allele of the BRCA2+/con1 cells, we constructed a targeting vector to delete all exons of the BRCA2 gene. The ∼6. kb and ∼3.5 kb fragments at the BRCA2 locus  were amplified from DT40 genomic DNA by using the 5′-CCGCTCGAGTTTTGTTAGTTGTGAGATGTG-3′ and 5′-TTATCGGGGCTTTGTCAGCTTTAGCTTCTC-3′ primers and the 5′-CGGAGTTGAATAATGGTACATTTCTGGCAC-3′ and 5′-GTTGAATTTGAAACTGGCTGAACAGAAGAG-3′ primers, respectively. Both fragments were cloned into TOPO-pCRXL cloning vector (Invitrogen, Carlsbad, California) to make the topo/6.0 kb and topo/3.5 kb vectors. The ∼5.2 kb NotI fragment from the topo/6.0 kb vector was inserted into the NotI site in the multicloning site of the topo/3.5 kb vector, resulting in the pUpper/Lower vector. Finally, a loxP-flanked puro-resistance cassette was inserted into the BglII site in the pUpper/Lower vector. The resulting targeting construct was transfected into the BRCA2+/con1 cells followed by selection with puromycin. The genomic DNA of the transfectants was digested with XbaI, and gene-targeting events were confirmed by Southern-blot analysis with a probe that was amplified from genomic DNA using the 5′-ATCCATGTCACTGTTGACATCCTGACTGCC-3′ and 5′-AGATACAAACCCAATGGGAAGCCAGGTGTG-3′ primers. The bands detected by the probe were 8.6 kb from the wild-type allele and 5.2 kb from the targeted allele.
Upon exposure of the BRCA2−/con1 cells to tamoxifen, an estrogen antagonist, nucleotide sequences, including promoter and coding sequences encoding the initiation codon to the 67th amino acid, were excised by a chimeric Cre recombinase fused to the estrogen-receptor ligand-binding domain , leading to the complete disruption of the BRCA2 gene.
Disruption of individual HR genes in BRCA2−/− DT40 cells
To disrupt RAD51 mediator genes in BRCA2−/− DT40 cells, we disrupted each gene in the BRCA2−/con1 cells (Table 1). We exposed the resulting RAD51 mediator−/−/BRCA2−/con1 cells to tamoxifen and isolated the RAD51 mediator−/−/BRCA2−/− cells.
Western blot analysis
Western blotting was performed as previously described . The rabbit polyclonal primary antibody, which recognizes the N-terminal 203 amino acids of chicken BRCA2, was diluted 1∶100 with blocking buffer. The anti-rabbit IgG HRP conjugated antibody was diluted 1∶5000 with blocking buffer.
To measure growth kinetics, cells were counted daily using flow-cytometric analysis, as described previously . To measure cell-cycle distribution, cells (5×105/ml) were labeled for 10 minutes with 20 µmol/L 5-bromo-2′-deoxyuridine (BrdU) and subsequently harvested. Harvested cells were fixed and analyzed as previously described .
Measurement of cellular sensitivity to camptothecin, cisplatin, and olaparib in liquid culture
To measure cellular survival, cells (1.5×103–1.5×104) were incubated in 1 ml culture medium per well containing various concentrations of the DNA-damaging agents. At 72 hours, the ATP in the cellular lysates was measured to assess the number of live cells. The camptothecin (TopoGen Inc., Colombus, OH) and olaparib (AstraZeneca) were diluted with DMSO, and the cisplatin (Nihonkayaku, Tokyo, Japan) was diluted with PBS. To measure the sensitivity of the DT40 cell lines to these agents, cells were continuously exposed to various concentrations of the drug and the number of cells was measured at 72 hours. At least three independent experiments were carried out. Sensitivity was calculated by dividing the number of cells treated with the drug by the number of untreated cells .
Measurement of ATP to assess cellular sensitivity to DNA damaging agents
To assess cell numbers after treatment with the genotoxic reagents, we measured the amount of ATP in the whole cell lysate .
Visualization of RAD51 foci
Cells were harvested at 3 hours after gamma irradiation. Cells were spun onto slides using a Shandon Cytospin 3 centrifuge (Shandon, Pittsburgh, Pa.). Staining and visualization of RAD51 foci were carried out as previously described  using rabbit polyclonal antibody, which recognizes human RAD51, at a dilution of 1∶500 (Calbiochem, San Diego, CA San Diego, CA), and Alexa Fluor 488 goat anti-human IgG antibody at a dilution of 1∶1000 (Molecular Probes Inc., Eugene, OR ).
Analysis of chromosomal aberrations
Measurement of chromosomal aberrations was performed as described previously .
Measurement of HR frequencies for I-Sce1–induced DSB repair
Measurement of recombination frequencies for I-SceI-induced DSB repair was performed as described previously , . Modified SCneo was inserted into the previously described OVALBUMIN gene construct and targeted into the OVALBUMIN locus in wild-type, xrcc3, brca1, brca2, and brca2tr DT40 clones. For transient transfections, 1×107 cells were suspended in 0.5 ml of phosphate-buffered saline, mixed with 30 µg of I-SceI expression vector (pCBASce) or pBluescript KS without linearization, and electroporated at 250 V, 960 microfarads. At 24 hours after electroporation, the cells were plated in 96-well plates with or without 2.0 mg/ml neomycin analog (G418). The cells were grown for 7 to 10 days, after which formed colonies were counted. HR frequency was calculated by dividing the number of neomycin-resistant colonies by the number of plated cells.
Survival data were log-transformed giving approximate normality. Analysis of covariance (ANCOVA) was used to test for differences in the linear dose-response curves between wild-type and a series of mutant cells or brca2-null cells and a series of double-knockout mutant cells. Viability of the DT40 cells was estimated using regressing curves. Regression-curve equations were used to calculate LC50 (50% lethal concentration) values. Relative LC50 values were normalized according to the LC50 value of the parental wild-type cells.
Generation of BRCA2−/− (ver.2) cells. (A) Experimental methods to generate BRCA2−/− (ver.2) cells. (B) Schematic representation of the BRCA2 conditional-null allele-2. The conditional-null allele-2 (con2) was generated by targeting the his selection-marker gene flanked by two loxP signals (ploxP-his) in intron 12 of the BRCA2 conditional allele 1. Treatment of the BRCA2−/con2 cells causes deletion from the promoter to exon 11, encoding all BRC motifs. The relevant XhoI sites in the conditional-null allele-1 and the position of the probe used in the Southern-blot analysis are indicated. The solid boxes and arrowheads represent the exons and loxP signals, respectively.
Proliferation and spontaneous chromosomal aberrations of brca2/rad52/xrcc3 triple knockout cells. (A) Growth kinetics of the indicated cell cultures in the absence (right) and presence (left) of TAM. Each value represents the averaged results from two separate clones. (B) Cell viability was assessed by flow cytometric analysis of PI uptake and forward scatter (FSC) representing the cell size after tamoxifen (TAM) treatment 4 days. A fixed number of plastic beads was added before flow cytometric analysis to calibrate cell number. Cells falling in the R1 and R2 gates identify dead and viable cells, respectively, and numbers given show their percentages. (C) Spontaneous chromosomal aberrations in cells with indicated genotype after tamoxifen (TAM) treatment 6 days. The data shown in the histogram indicate the types and numbers of chromosomal breaks in 50 analyzed mitotic cells. Two breaks at the same site of both sister chromatids are defined as isochromatid breaks, while breaks at either sister chromatid are chromatid breaks.
Conceived and designed the experiments: YQ MY KH ST. Performed the experiments: YQ MY KH DD KNY. Analyzed the data: YQ MY KH DKB XW ST. Contributed reagents/materials/analysis tools: YQ MY KH WS DD KNY XW. Wrote the paper: YQ MY KH ST.
- 1. Sonoda E, Sasaki MS, Buerstedde JM, Bezzubova O, Shinohara A, et al. (1998) Rad51-deficient vertebrate cells accumulate chromosomal breaks prior to cell death. EMBO J 17: 598–608.E. SonodaMS SasakiJM BuersteddeO. BezzubovaA. Shinohara1998Rad51-deficient vertebrate cells accumulate chromosomal breaks prior to cell death.EMBO J17598608
- 2. Yamazoe M, Sonoda E, Hochegger H, Takeda S (2004) Reverse genetic studies of the DNA damage response in the chicken B lymphocyte line DT40. DNA Repair (Amst) 3: 1175–1185.M. YamazoeE. SonodaH. HocheggerS. Takeda2004Reverse genetic studies of the DNA damage response in the chicken B lymphocyte line DT40.DNA Repair (Amst)311751185
- 3. Venkitaraman AR (2009) Linking the cellular functions of BRCA genes to cancer pathogenesis and treatment. Annu Rev Pathol 4: 461–487.AR Venkitaraman2009Linking the cellular functions of BRCA genes to cancer pathogenesis and treatment.Annu Rev Pathol4461487
- 4. Branzei D, Vanoli F, Foiani M (2008) SUMOylation regulates Rad18-mediated template switch. Nature 456: 915–920.D. BranzeiF. VanoliM. Foiani2008SUMOylation regulates Rad18-mediated template switch.Nature456915920
- 5. Caldecott KW (2008) Single-strand break repair and genetic disease. Nat Rev Genet 9: 619–631.KW Caldecott2008Single-strand break repair and genetic disease.Nat Rev Genet9619631
- 6. Ashworth A (2008) Drug resistance caused by reversion mutation. Cancer Res 68: 10021–10023.A. Ashworth2008Drug resistance caused by reversion mutation.Cancer Res681002110023
- 7. Takata M, Sasaki MS, Sonoda E, Morrison C, Hashimoto M, et al. (1998) Homologous recombination and non-homologous end-joining pathways of DNA double-strand break repair have overlapping roles in the maintenance of chromosomal integrity in vertebrate cells. EMBO J 17: 5497–5508.M. TakataMS SasakiE. SonodaC. MorrisonM. Hashimoto1998Homologous recombination and non-homologous end-joining pathways of DNA double-strand break repair have overlapping roles in the maintenance of chromosomal integrity in vertebrate cells.EMBO J1754975508
- 8. Nojima K, Hochegger H, Saberi A, Fukushima T, Kikuchi K, et al. (2005) Multiple repair pathways mediate tolerance to chemotherapeutic cross-linking agents in vertebrate cells. Cancer Res 65: 11704–11711.K. NojimaH. HocheggerA. SaberiT. FukushimaK. Kikuchi2005Multiple repair pathways mediate tolerance to chemotherapeutic cross-linking agents in vertebrate cells.Cancer Res651170411711
- 9. Adachi N, So S, Koyama H (2004) Loss of nonhomologous end joining confers camptothecin resistance in DT40 cells. Implications for the repair of topoisomerase I-mediated DNA damage. J Biol Chem 279: 37343–37348.N. AdachiS. SoH. Koyama2004Loss of nonhomologous end joining confers camptothecin resistance in DT40 cells. Implications for the repair of topoisomerase I-mediated DNA damage.J Biol Chem2793734337348
- 10. Paques F, Haber JE (1999) Multiple pathways of recombination induced by double-strand breaks in Saccharomyces cerevisiae. Microbiol Mol Biol Rev 63: 349–404.F. PaquesJE Haber1999Multiple pathways of recombination induced by double-strand breaks in Saccharomyces cerevisiae.Microbiol Mol Biol Rev63349404
- 11. Takeda S, Nakamura K, Taniguchi Y, Paull TT (2007) Ctp1/CtIP and the MRN complex collaborate in the initial steps of homologous recombination. Mol Cell 28: 351–352.S. TakedaK. NakamuraY. TaniguchiTT Paull2007Ctp1/CtIP and the MRN complex collaborate in the initial steps of homologous recombination.Mol Cell28351352
- 12. Sartori AA, Lukas C, Coates J, Mistrik M, Fu S, et al. (2007) Human CtIP promotes DNA end resection. Nature 450: 509–514.AA SartoriC. LukasJ. CoatesM. MistrikS. Fu2007Human CtIP promotes DNA end resection.Nature450509514
- 13. Bernstein KA, Rothstein R (2009) At loose ends: resecting a double-strand break. Cell 137: 807–810.KA BernsteinR. Rothstein2009At loose ends: resecting a double-strand break.Cell137807810
- 14. Yun MH, Hiom K (2009) CtIP-BRCA1 modulates the choice of DNA double-strand-break repair pathway throughout the cell cycle. Nature 459: 460–463.MH YunK. Hiom2009CtIP-BRCA1 modulates the choice of DNA double-strand-break repair pathway throughout the cell cycle.Nature459460463
- 15. Nakamura K, Kogame T, Oshiumi H, Shinohara A, Sumitomo Y, et al. (2010) Collaborative action of Brca1 and CtIP in elimination of covalent modifications from double-strand breaks to facilitate subsequent break repair. PLoS Genet 6: e1000828.K. NakamuraT. KogameH. OshiumiA. ShinoharaY. Sumitomo2010Collaborative action of Brca1 and CtIP in elimination of covalent modifications from double-strand breaks to facilitate subsequent break repair.PLoS Genet6e1000828
- 16. Nimonkar AV, Genschel J, Kinoshita E, Polaczek P, Campbell JL, et al. (2011) BLM-DNA2-RPA-MRN and EXO1-BLM-RPA-MRN constitute two DNA end resection machineries for human DNA break repair. Genes Dev 25: 350–362.AV NimonkarJ. GenschelE. KinoshitaP. PolaczekJL Campbell2011BLM-DNA2-RPA-MRN and EXO1-BLM-RPA-MRN constitute two DNA end resection machineries for human DNA break repair.Genes Dev25350362
- 17. Mimitou EP, Symington LS (2011) DNA end resection–unraveling the tail. DNA Repair (Amst) 10: 344–348.EP MimitouLS Symington2011DNA end resection–unraveling the tail.DNA Repair (Amst)10344348
- 18. Kawamoto T, Araki K, Sonoda E, Yamashita YM, Harada K, et al. (2005) Dual roles for DNA polymerase eta in homologous DNA recombination and translesion DNA synthesis. Mol Cell 20: 793–799.T. KawamotoK. ArakiE. SonodaYM YamashitaK. Harada2005Dual roles for DNA polymerase eta in homologous DNA recombination and translesion DNA synthesis.Mol Cell20793799
- 19. McIlwraith MJ, Vaisman A, Liu Y, Fanning E, Woodgate R, et al. (2005) Human DNA polymerase eta promotes DNA synthesis from strand invasion intermediates of homologous recombination. Mol Cell 20: 783–792.MJ McIlwraithA. VaismanY. LiuE. FanningR. Woodgate2005Human DNA polymerase eta promotes DNA synthesis from strand invasion intermediates of homologous recombination.Mol Cell20783792
- 20. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, et al. (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378: 789–792.R. WoosterG. BignellJ. LancasterS. SwiftS. Seal1995Identification of the breast cancer susceptibility gene BRCA2.Nature378789792
- 21. Miki Y, Katagiri T, Kasumi F, Yoshimoto T, Nakamura Y (1996) Mutation analysis in the BRCA2 gene in primary breast cancers. Nat Genet 13: 245–247.Y. MikiT. KatagiriF. KasumiT. YoshimotoY. Nakamura1996Mutation analysis in the BRCA2 gene in primary breast cancers.Nat Genet13245247
- 22. Bhattacharyya A, Ear US, Koller BH, Weichselbaum RR, Bishop DK (2000) The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 275: 23899–23903.A. BhattacharyyaUS EarBH KollerRR WeichselbaumDK Bishop2000The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin.J Biol Chem2752389923903
- 23. Bishop DK, Ear U, Bhattacharyya A, Calderone C, Beckett M, et al. (1998) Xrcc3 is required for assembly of Rad51 complexes in vivo. J Biol Chem 273: 21482–21488.DK BishopU. EarA. BhattacharyyaC. CalderoneM. Beckett1998Xrcc3 is required for assembly of Rad51 complexes in vivo.J Biol Chem2732148221488
- 24. Fujimori A, Tachiiri S, Sonoda E, Thompson LH, Dhar PK, et al. (2001) Rad52 partially substitutes for the Rad51 paralog XRCC3 in maintaining chromosomal integrity in vertebrate cells. EMBO J 20: 5513–5520.A. FujimoriS. TachiiriE. SonodaLH ThompsonPK Dhar2001Rad52 partially substitutes for the Rad51 paralog XRCC3 in maintaining chromosomal integrity in vertebrate cells.EMBO J2055135520
- 25. Akamatsu Y, Tsutsui Y, Morishita T, Siddique MS, Kurokawa Y, et al. (2007) Fission yeast Swi5/Sfr1 and Rhp55/Rhp57 differentially regulate Rhp51-dependent recombination outcomes. EMBO J 26: 1352–1362.Y. AkamatsuY. TsutsuiT. MorishitaMS SiddiqueY. Kurokawa2007Fission yeast Swi5/Sfr1 and Rhp55/Rhp57 differentially regulate Rhp51-dependent recombination outcomes.EMBO J2613521362
- 26. Martin V, Chahwan C, Gao H, Blais V, Wohlschlegel J, et al. (2006) Sws1 is a conserved regulator of homologous recombination in eukaryotic cells. EMBO J 25: 2564–2574.V. MartinC. ChahwanH. GaoV. BlaisJ. Wohlschlegel2006Sws1 is a conserved regulator of homologous recombination in eukaryotic cells.EMBO J2525642574
- 27. Xia B, Sheng Q, Nakanishi K, Ohashi A, Wu J, et al. (2006) Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell 22: 719–729.B. XiaQ. ShengK. NakanishiA. OhashiJ. Wu2006Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2.Mol Cell22719729
- 28. Thorslund T, West SC (2007) BRCA2: a universal recombinase regulator. Oncogene 26: 7720–7730.T. ThorslundSC West2007BRCA2: a universal recombinase regulator.Oncogene2677207730
- 29. Forget AL, Kowalczykowski SC (2010) Single-molecule imaging brings Rad51 nucleoprotein filaments into focus. Trends Cell Biol 20: 269–276.AL ForgetSC Kowalczykowski2010Single-molecule imaging brings Rad51 nucleoprotein filaments into focus.Trends Cell Biol20269276
- 30. Shivji MK, Davies OR, Savill JM, Bates DL, Pellegrini L, et al. (2006) A region of human BRCA2 containing multiple BRC repeats promotes RAD51-mediated strand exchange. Nucleic Acids Res 34: 4000–4011.MK ShivjiOR DaviesJM SavillDL BatesL. Pellegrini2006A region of human BRCA2 containing multiple BRC repeats promotes RAD51-mediated strand exchange.Nucleic Acids Res3440004011
- 31. Carreira A, Hilario J, Amitani I, Baskin RJ, Shivji MK, et al. (2009) The BRC repeats of BRCA2 modulate the DNA-binding selectivity of RAD51. Cell 136: 1032–1043.A. CarreiraJ. HilarioI. AmitaniRJ BaskinMK Shivji2009The BRC repeats of BRCA2 modulate the DNA-binding selectivity of RAD51.Cell13610321043
- 32. Connor F, Bertwistle D, Mee PJ, Ross GM, Swift S, et al. (1997) Tumorigenesis and a DNA repair defect in mice with a truncating Brca2 mutation. Nat Genet 17: 423–430.F. ConnorD. BertwistlePJ MeeGM RossS. Swift1997Tumorigenesis and a DNA repair defect in mice with a truncating Brca2 mutation.Nat Genet17423430
- 33. Hatanaka A, Yamazoe M, Sale JE, Takata M, Yamamoto K, et al. (2005) Similar effects of Brca2 truncation and Rad51 paralog deficiency on immunoglobulin V gene diversification in DT40 cells support an early role for Rad51 paralogs in homologous recombination. Mol Cell Biol 25: 1124–1134.A. HatanakaM. YamazoeJE SaleM. TakataK. Yamamoto2005Similar effects of Brca2 truncation and Rad51 paralog deficiency on immunoglobulin V gene diversification in DT40 cells support an early role for Rad51 paralogs in homologous recombination.Mol Cell Biol2511241134
- 34. Zhao GY, Sonoda E, Barber LJ, Oka H, Murakawa Y, et al. (2007) A critical role for the ubiquitin-conjugating enzyme Ubc13 in initiating homologous recombination. Mol Cell 25: 663–675.GY ZhaoE. SonodaLJ BarberH. OkaY. Murakawa2007A critical role for the ubiquitin-conjugating enzyme Ubc13 in initiating homologous recombination.Mol Cell25663675
- 35. Takata M, Sasaki MS, Sonoda E, Fukushima T, Morrison C, et al. (2000) The Rad51 paralog Rad51B promotes homologous recombinational repair. Mol Cell Biol 20: 6476–6482.M. TakataMS SasakiE. SonodaT. FukushimaC. Morrison2000The Rad51 paralog Rad51B promotes homologous recombinational repair.Mol Cell Biol2064766482
- 36. Yonetani Y, Hochegger H, Sonoda E, Shinya S, Yoshikawa H, et al. (2005) Differential and collaborative actions of Rad51 paralog proteins in cellular response to DNA damage. Nucleic Acids Res 33: 4544–4552.Y. YonetaniH. HocheggerE. SonodaS. ShinyaH. Yoshikawa2005Differential and collaborative actions of Rad51 paralog proteins in cellular response to DNA damage.Nucleic Acids Res3345444552
- 37. Murayama Y, Kurokawa Y, Mayanagi K, Iwasaki H (2008) Formation and branch migration of Holliday junctions mediated by eukaryotic recombinases. Nature 451: 1018–1021.Y. MurayamaY. KurokawaK. MayanagiH. Iwasaki2008Formation and branch migration of Holliday junctions mediated by eukaryotic recombinases.Nature45110181021
- 38. Kurokawa Y, Murayama Y, Haruta-Takahashi N, Urabe I, Iwasaki H (2008) Reconstitution of DNA strand exchange mediated by Rhp51 recombinase and two mediators. PLoS Biol 6: e88.Y. KurokawaY. MurayamaN. Haruta-TakahashiI. UrabeH. Iwasaki2008Reconstitution of DNA strand exchange mediated by Rhp51 recombinase and two mediators.PLoS Biol6e88
- 39. Akamatsu Y, Jasin M (2010) Role for the mammalian Swi5-Sfr1 complex in DNA strand break repair through homologous recombination. PLoS Genet 6: e1001160.Y. AkamatsuM. Jasin2010Role for the mammalian Swi5-Sfr1 complex in DNA strand break repair through homologous recombination.PLoS Genet6e1001160
- 40. Liu J, Doty T, Gibson B, Heyer WD (2010) Human BRCA2 protein promotes RAD51 filament formation on RPA-covered single-stranded DNA. Nat Struct Mol Biol 17: 1260–1262.J. LiuT. DotyB. GibsonWD Heyer2010Human BRCA2 protein promotes RAD51 filament formation on RPA-covered single-stranded DNA.Nat Struct Mol Biol1712601262
- 41. Thorslund T, McIlwraith MJ, Compton SA, Lekomtsev S, Petronczki M, et al. (2010) The breast cancer tumor suppressor BRCA2 promotes the specific targeting of RAD51 to single-stranded DNA. Nat Struct Mol Biol 17: 1263–1265.T. ThorslundMJ McIlwraithSA ComptonS. LekomtsevM. Petronczki2010The breast cancer tumor suppressor BRCA2 promotes the specific targeting of RAD51 to single-stranded DNA.Nat Struct Mol Biol1712631265
- 42. Jensen RB, Carreira A, Kowalczykowski SC (2010) Purified human BRCA2 stimulates RAD51-mediated recombination. Nature 467: 678–683.RB JensenA. CarreiraSC Kowalczykowski2010Purified human BRCA2 stimulates RAD51-mediated recombination.Nature467678683
- 43. Buerstedde JM, Takeda S (1991) Increased ratio of targeted to random integration after transfection of chicken B cell lines. Cell 67: 179–188.JM BuersteddeS. Takeda1991Increased ratio of targeted to random integration after transfection of chicken B cell lines.Cell67179188
- 44. Fukushima T, Takata M, Morrison C, Araki R, Fujimori A, et al. (2001) Genetic analysis of the DNA-dependent protein kinase reveals an inhibitory role of Ku in late S-G2 phase DNA double-strand break repair. J Biol Chem 276: 44413–44418.T. FukushimaM. TakataC. MorrisonR. ArakiA. Fujimori2001Genetic analysis of the DNA-dependent protein kinase reveals an inhibitory role of Ku in late S-G2 phase DNA double-strand break repair.J Biol Chem2764441344418
- 45. Moynahan ME, Pierce AJ, Jasin M (2001) BRCA2 is required for homology-directed repair of chromosomal breaks. Mol Cell 7: 263–272.ME MoynahanAJ PierceM. Jasin2001BRCA2 is required for homology-directed repair of chromosomal breaks.Mol Cell7263272
- 46. Martin RW, Orelli BJ, Yamazoe M, Minn AJ, Takeda S, et al. (2007) RAD51 up-regulation bypasses BRCA1 function and is a common feature of BRCA1-deficient breast tumors. Cancer Res 67: 9658–9665.RW MartinBJ OrelliM. YamazoeAJ MinnS. Takeda2007RAD51 up-regulation bypasses BRCA1 function and is a common feature of BRCA1-deficient breast tumors.Cancer Res6796589665
- 47. Mazin AV, Mazina OM, Bugreev DV, Rossi MJ (2010) Rad54, the motor of homologous recombination. DNA Repair (Amst) 9: 286–302.AV MazinOM MazinaDV BugreevMJ Rossi2010Rad54, the motor of homologous recombination.DNA Repair (Amst)9286302
- 48. Wechsler T, Newman S, West SC (2011) Aberrant chromosome morphology in human cells defective for Holliday junction resolution. Nature 471: 642–646.T. WechslerS. NewmanSC West2011Aberrant chromosome morphology in human cells defective for Holliday junction resolution.Nature471642646
- 49. Feng Z, Scott SP, Bussen W, Sharma GG, Guo G, et al. (2011) Rad52 inactivation is synthetically lethal with BRCA2 deficiency. Proc Natl Acad Sci U S A 108: 686–691.Z. FengSP ScottW. BussenGG SharmaG. Guo2011Rad52 inactivation is synthetically lethal with BRCA2 deficiency.Proc Natl Acad Sci U S A108686691
- 50. Kojic M, Kostrub CF, Buchman AR, Holloman WK (2002) BRCA2 homolog required for proficiency in DNA repair, recombination, and genome stability in Ustilago maydis. Mol Cell 10: 683–691.M. KojicCF KostrubAR BuchmanWK Holloman2002BRCA2 homolog required for proficiency in DNA repair, recombination, and genome stability in Ustilago maydis.Mol Cell10683691
- 51. Siaud N, Dray E, Gy I, Gerard E, Takvorian N, et al. (2004) Brca2 is involved in meiosis in Arabidopsis thaliana as suggested by its interaction with Dmc1. EMBO J 23: 1392–1401.N. SiaudE. DrayI. GyE. GerardN. Takvorian2004Brca2 is involved in meiosis in Arabidopsis thaliana as suggested by its interaction with Dmc1.EMBO J2313921401
- 52. Lim DS, Hasty P (1996) A mutation in mouse rad51 results in an early embryonic lethal that is suppressed by a mutation in p53. Mol Cell Biol 16: 7133–7143.DS LimP. Hasty1996A mutation in mouse rad51 results in an early embryonic lethal that is suppressed by a mutation in p53.Mol Cell Biol1671337143
- 53. Ludwig T, Chapman DL, Papaioannou VE, Efstratiadis A (1997) Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos. Genes Dev 11: 1226–1241.T. LudwigDL ChapmanVE PapaioannouA. Efstratiadis1997Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos.Genes Dev1112261241
- 54. Ludwig T, Fisher P, Murty V, Efstratiadis A (2001) Development of mammary adenocarcinomas by tissue-specific knockout of Brca2 in mice. Oncogene 20: 3937–3948.T. LudwigP. FisherV. MurtyA. Efstratiadis2001Development of mammary adenocarcinomas by tissue-specific knockout of Brca2 in mice.Oncogene2039373948
- 55. Cheung AM, Elia A, Tsao MS, Done S, Wagner KU, et al. (2004) Brca2 deficiency does not impair mammary epithelium development but promotes mammary adenocarcinoma formation in p53(+/-) mutant mice. Cancer Res 64: 1959–1965.AM CheungA. EliaMS TsaoS. DoneKU Wagner2004Brca2 deficiency does not impair mammary epithelium development but promotes mammary adenocarcinoma formation in p53(+/-) mutant mice.Cancer Res6419591965
- 56. D'Andrea AD (2010) Susceptibility pathways in Fanconi's anemia and breast cancer. N Engl J Med 362: 1909–1919.AD D'Andrea2010Susceptibility pathways in Fanconi's anemia and breast cancer.N Engl J Med36219091919
- 57. Huen MS, Sy SM, Chen J (2010) BRCA1 and its toolbox for the maintenance of genome integrity. Nat Rev Mol Cell Biol 11: 138–148.MS HuenSM SyJ. Chen2010BRCA1 and its toolbox for the maintenance of genome integrity.Nat Rev Mol Cell Biol11138148
- 58. Sy SM, Huen MS, Chen J (2009) PALB2 is an integral component of the BRCA complex required for homologous recombination repair. Proc Natl Acad Sci U S A 106: 7155–7160.SM SyMS HuenJ. Chen2009PALB2 is an integral component of the BRCA complex required for homologous recombination repair.Proc Natl Acad Sci U S A10671557160
- 59. Bunting SF, Callen E, Wong N, Chen HT, Polato F, et al. (2010) 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell 141: 243–254.SF BuntingE. CallenN. WongHT ChenF. Polato201053BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks.Cell141243254
- 60. Spies M, Kowalczykowski SC (2006) The RecA binding locus of RecBCD is a general domain for recruitment of DNA strand exchange proteins. Mol Cell 21: 573–580.M. SpiesSC Kowalczykowski2006The RecA binding locus of RecBCD is a general domain for recruitment of DNA strand exchange proteins.Mol Cell21573580
- 61. Yang H, Li Q, Fan J, Holloman WK, Pavletich NP (2005) The BRCA2 homologue Brh2 nucleates RAD51 filament formation at a dsDNA-ssDNA junction. Nature 433: 653–657.H. YangQ. LiJ. FanWK HollomanNP Pavletich2005The BRCA2 homologue Brh2 nucleates RAD51 filament formation at a dsDNA-ssDNA junction.Nature433653657
- 62. Kohzaki M, Nishihara K, Hirota K, Sonoda E, Yoshimura M, et al. (2010) DNA polymerases nu and theta are required for efficient immunoglobulin V gene diversification in chicken. J Cell Biol 189: 1117–1127.M. KohzakiK. NishiharaK. HirotaE. SonodaM. Yoshimura2010DNA polymerases nu and theta are required for efficient immunoglobulin V gene diversification in chicken.J Cell Biol18911171127
- 63. Takao N, Kato H, Mori R, Morrison C, Sonada E, et al. (1999) Disruption of ATM in p53-null cells causes multiple functional abnormalities in cellular response to ionizing radiation. Oncogene 18: 7002–7009.N. TakaoH. KatoR. MoriC. MorrisonE. Sonada1999Disruption of ATM in p53-null cells causes multiple functional abnormalities in cellular response to ionizing radiation.Oncogene1870027009
- 64. Yoshimura M, Kohzaki M, Nakamura J, Asagoshi K, Sonoda E, et al. (2006) Vertebrate POLQ and POLbeta cooperate in base excision repair of oxidative DNA damage. Mol Cell 24: 115–125.M. YoshimuraM. KohzakiJ. NakamuraK. AsagoshiE. Sonoda2006Vertebrate POLQ and POLbeta cooperate in base excision repair of oxidative DNA damage.Mol Cell24115125
- 65. Iiizumi S, Nomura Y, So S, Uegaki K, Aoki K, et al. (2006) Simple one-week method to construct gene-targeting vectors: application to production of human knockout cell lines. Biotechniques 41: 311–316.S. IiizumiY. NomuraS. SoK. UegakiK. Aoki2006Simple one-week method to construct gene-targeting vectors: application to production of human knockout cell lines.Biotechniques41311316
- 66. Takata M, Tachiiri S, Fujimori A, Thompson LH, Miki Y, et al. (2002) Conserved domains in the chicken homologue of BRCA2. Oncogene 21: 1130–1134.M. TakataS. TachiiriA. FujimoriLH ThompsonY. Miki2002Conserved domains in the chicken homologue of BRCA2.Oncogene2111301134
- 67. Ji K, Kogame T, Choi K, Wang X, Lee J, et al. (2009) A novel approach using DNA-repair-deficient chicken DT40 cell lines for screening and characterizing the genotoxicity of environmental contaminants. Environ Health Perspect 117: 1737–1744.K. JiT. KogameK. ChoiX. WangJ. Lee2009A novel approach using DNA-repair-deficient chicken DT40 cell lines for screening and characterizing the genotoxicity of environmental contaminants.Environ Health Perspect11717371744
- 68. Sonoda E, Okada T, Zhao GY, Tateishi S, Araki K, et al. (2003) Multiple roles of Rev3, the catalytic subunit of polzeta in maintaining genome stability in vertebrates. EMBO J 22: 3188–3197.E. SonodaT. OkadaGY ZhaoS. TateishiK. Araki2003Multiple roles of Rev3, the catalytic subunit of polzeta in maintaining genome stability in vertebrates.EMBO J2231883197
- 69. Yamaguchi-Iwai Y, Sonoda E, Buerstedde JM, Bezzubova O, Morrison C, et al. (1998) Homologous recombination, but not DNA repair, is reduced in vertebrate cells deficient in RAD52. Mol Cell Biol 18: 6430–6435.Y. Yamaguchi-IwaiE. SonodaJM BuersteddeO. BezzubovaC. Morrison1998Homologous recombination, but not DNA repair, is reduced in vertebrate cells deficient in RAD52.Mol Cell Biol1864306435
- 70. Bezzubova O, Silbergleit A, Yamaguchi-Iwai Y, Takeda S, Buerstedde JM (1997) Reduced X-ray resistance and homologous recombination frequencies in a RAD54-/- mutant of the chicken DT40 cell line. Cell 89: 185–193.O. BezzubovaA. SilbergleitY. Yamaguchi-IwaiS. TakedaJM Buerstedde1997Reduced X-ray resistance and homologous recombination frequencies in a RAD54-/- mutant of the chicken DT40 cell line.Cell89185193
- 71. Takata M, Sasaki MS, Tachiiri S, Fukushima T, Sonoda E, et al. (2001) Chromosome instability and defective recombinational repair in knockout mutants of the five Rad51 paralogs. Mol Cell Biol 21: 2858–2866.M. TakataMS SasakiS. TachiiriT. FukushimaE. Sonoda2001Chromosome instability and defective recombinational repair in knockout mutants of the five Rad51 paralogs.Mol Cell Biol2128582866